Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. - Wikidata - awgldk - TriplyDB

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

http://www.wikidata.org/entity/Q53578474

about

Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management Sarcoidosis mimicking metastatic progression of pancreatic neuroendocrine tumor: A case report.AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Principles of diagnosis and management of neuroendocrine tumours.Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach.Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

P2860

Q26795597-C880ECAF-EB63-4216-83DB-1E51FF729294 Q33879711-5DF0BE94-3B99-46DE-9DC4-95DEB00E185B Q36659064-3FAF7DE4-27C5-4591-B4A7-2BBD096EDC18 Q37109909-76B8B7D2-428C-477E-A639-DD57F354BD13 Q38727852-BCA35529-94C8-4533-B4ED-8547DF9E2F74 Q39016753-4C29323C-9BAE-4B15-8303-68D34D222967 Q39225250-CF5A3687-1D1E-4304-BFC8-F59F93D8A2A9 Q40051095-E660E587-AF8A-427F-8549-F8AE12FE2A27 Q41646599-BCD0C2F0-DE5F-4128-BCFC-7E23831DF839 Q51578965-C29629D3-7D00-4EDC-B348-FB96DC6E7564 Q52717653-DC1BC181-47A0-46C5-BB19-F717EB0A62D1 Q53682879-30F6D23B-7C2A-4B6A-9723-47F2EE5E82C4

P2860

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

http://www.wikidata.org/entity/Q53578474

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@en

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@nl

type

label

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@en

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@nl

prefLabel

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@en

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@nl

P1433

Q53578474-F2C9D80D-D886-43C3-A728-2B1590936A4D

P1476

Q53578474-3D6AA715-4748-4405-84F5-E6E46CB61D1D

P2093

Q53578474-42B4AF79-4CE6-4EA6-BB96-4167415B0DA5

Q53578474-48485458-E16A-4299-A997-F5806E632EDA

Q53578474-5CBDF573-F2C6-4C4B-83A9-58B5E19D2AE3

Q53578474-64BFF7B8-C87E-4477-B720-4C12BE80C12A

Q53578474-68364BE2-872B-4532-B690-5E963DFBB6C9

Q53578474-69315D67-A1BE-49BD-8414-849EE44648F6

Q53578474-6D86012F-327D-45AE-B53E-269EE381DB9F

Q53578474-A02D6875-5C12-42DF-875C-6B005B376D04

Q53578474-BEBE4A26-DE24-4027-9962-6CDF2EE88E6C

Q53578474-BFBACEA7-A5FE-4F00-B69E-20C781D5781F

P2860

Q53578474-0A5529A3-9DB2-4A7B-8BF7-FDE3F8754ECE

Q53578474-10E6356D-943B-4E40-8EF7-8F7196375348

Q53578474-15D2E327-C7D8-4D5A-BBFD-F82B154C8A58

Q53578474-2527EF2F-9652-4DF3-B3A7-F600219BBFCA

Q53578474-2BC3EFBC-35F6-4486-8C7C-D3C623C1DBEF

Q53578474-3B88251E-C2F4-4414-BEE4-635BA91FEE20

Q53578474-42870B6E-53C4-4EE8-AAD2-0254EBE20773

Q53578474-513F8716-02B6-4133-BC24-339B3952B1CE

Q53578474-52156535-5803-4559-95CD-81BA7FFEEF95

Q53578474-57AFEDBF-7520-4480-B7C7-F1030D0BEC59

P2888

Q53578474-7B9E079B-0795-4CAA-BA8C-BB0EEB04D9D4

P304

Q53578474-60057692-07D2-4ECD-8D81-45383AA3734C

P31

Q53578474-66EAC27A-4EE9-4284-8C14-80AC0F9528B5

P356

Q53578474-F092C360-1C5E-45E7-8DF4-2E85D1041CD4

P433

Q53578474-7DB62780-CA2E-46FF-8ACB-FA1538185711

P478

Q53578474-B837E876-EF1E-445B-A172-27DBF694FF4E

P50

Q53578474-79BCA845-E4B0-4156-BB4A-743BA1522818

P577

Q53578474-C6B5AEB5-4566-410D-AF19-56269F226663

P6179

Q53578474-94F20322-D499-4B57-825B-6F7C7738D607

P698

Q53578474-C697CDEF-70FD-440A-90BE-A548B575D639

P356

S10434-015-4471-X

P1433

Annals of Surgical Oncology

P1476

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

@en

P2093

Bassel El-Rayes

http://www.w3.org/2001/XMLSchema#string

Charles A Staley

http://www.w3.org/2001/XMLSchema#string

David A Kooby

http://www.w3.org/2001/XMLSchema#string

Deniz Altinel

http://www.w3.org/2001/XMLSchema#string

Joshua H Winer

http://www.w3.org/2001/XMLSchema#string

Juan M Sarmiento

http://www.w3.org/2001/XMLSchema#string

Keith A Delman

http://www.w3.org/2001/XMLSchema#string

Kenneth Cardona

http://www.w3.org/2001/XMLSchema#string

Malcolm H Squires

http://www.w3.org/2001/XMLSchema#string

Maria C Russell

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis

Imaging of neuroendocrine tumors

Gastroenteropancreatic neuroendocrine tumours

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

Current knowledge on diagnosis and staging of neuroendocrine tumors

Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

The role of PET in localization of neuroendocrine and adrenocortical tumors.

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.

P2888

s10434-015-4471-x

P304

2295-2301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-015-4471-X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

David M Schuster

P577

2015-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002485210

http://www.w3.org/2001/XMLSchema#string

P698

25786743

http://www.w3.org/2001/XMLSchema#string